Innate Pharma (IPHA) Non-Current Deferred Tax Liability (2018 - 2024)

Innate Pharma (IPHA) has reported Non-Current Deferred Tax Liability for 7 consecutive years, with $10.4 million the latest figure, recorded in Q2 2024.

• Quarterly Non-Current Deferred Tax Liability fell 5.7% year-over-year to $10.4 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $10.4 million (down 5.7% YoY) and the FY2023 annual result came in at $10.2 million, up 5.11% from the prior year.
• Non-Current Deferred Tax Liability improved to $10.4 million in Q2 2024 per IPHA's latest filing, from $10.2 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for IPHA reached as high as $1.3 billion in Q2 2020 and fell as low as $5.7 million in Q4 2021.
• A 5-year average of $148.8 million and a median of $9.7 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2020 — Non-Current Deferred Tax Liability soared 451.09% — and 2021, when it slumped 99.52%.
• Year by year, Non-Current Deferred Tax Liability stood at $8.1 million in 2020, then decreased by 29.05% to $5.7 million in 2021, then soared by 70.41% to $9.7 million in 2022, then climbed by 5.11% to $10.2 million in 2023, then climbed by 1.3% to $10.4 million in 2024.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $10.4 million, $10.2 million, and $11.0 million for Q2 2024, Q4 2023, and Q2 2023 respectively.